Patents by Inventor Paul Parren

Paul Parren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
    Patent number: 10323081
    Abstract: Provided are antibody variants having decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to the presence or absence of C-terminal lysines of their heavy chains. Also provided are methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of such antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 18, 2019
    Assignee: GENMAG A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald T. J. Van Den Bremer
  • Human Antibodies Against Tissue Factor and Methods of Use Thereof
    Publication number: 20190169311
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: August 16, 2018
    Publication date: June 6, 2019
    Inventors: Sandra Verploegen, David P.E. Satijn, Rene M.A. Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20190169298
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: November 7, 2018
    Publication date: June 6, 2019
    Inventors: Paul PARREN, Janine SCHUURMAN, Tom VINK, Willem Karel BLEEKER, Jan VAN DE WINKEL, Patrick VAN BERKEL, Frank BEURSKENS
  • ANTIBODIES BINDING AXL
    Publication number: 20190160170
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: February 7, 2019
    Publication date: May 30, 2019
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190144554
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: December 1, 2016
    Publication date: May 16, 2019
    Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Patent number: 10253093
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: April 9, 2019
    Assignee: CORMORANT PHARMACEUTICALS AB
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen
  • Antibodies binding AXL
    Patent number: 10201607
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 12, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20190022243
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • AGENTS, USES AND METHODS FOR TREATMENT
    Publication number: 20190023788
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Application
    Filed: July 17, 2018
    Publication date: January 24, 2019
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
  • Recombinant monovalent antibodies and methods for production thereof
    Patent number: 10155816
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: December 18, 2018
    Assignee: GENMAB A/S
    Inventors: Paul Parren, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20180326084
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 15, 2018
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Henrik Jørn DITZEL, Paul PARREN
  • ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION
    Publication number: 20180319888
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 8, 2018
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20180305455
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 12, 2016
    Publication date: October 25, 2018
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey b. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward Van Den Brink, Paul Parren, Rob De Jong
  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20180298106
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 18, 2018
    Inventors: Michel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20180258173
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 13, 2018
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20180251540
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 30, 2018
    Publication date: September 6, 2018
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Patent number: 10066012
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: September 4, 2018
    Assignee: CORMORANT PHARMACEUTICALS AB
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen
  • ANTIBODIES BINDING AXL
    Publication number: 20180214549
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20180215827
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: August 2, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • BISPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD FOR ISOLATION OF SUCH
    Publication number: 20180201693
    Abstract: Bispecific and multispecific antibodies having differentially modified light chains, that allows for isolation of the bispecific or multispecific antibodies based on a differential affinity towards an affinity reagent.
    Type: Application
    Filed: July 1, 2016
    Publication date: July 19, 2018
    Inventors: Richard G. HIBBERT, Aran F. LABRIJN, Arnout F. GERRITSEN, Janine SCHUURMAN, Paul PARREN